Expertise in
9
conditions

Dr. Maria Q. Baggstrom

Oncology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Accepting New Patients
Expertise in
9
conditions
Washington University
660 S Euclid Ave, 
Saint Louis, MO 

Overview

Maria Baggstrom is an Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Baggstrom is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Gastrostomy, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 18 clinical trials. Dr. Baggstrom is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish West County Hospital
Barnes Jewish Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: APL-101, Osimertinib
Study Phase: Phase 1/Phase 2
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Device, Biological, Radiation
Study Drugs: Paclitaxel, Carboplatin AUC, Durvalumab
Study Phase: Phase 2
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2025
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Neoantigen DNA Vaccine, Durvalumab
Study Phase: Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Enrollment Status: Completed
Publish Date: July 30, 2024
Intervention Type: Drug, Procedure
Study Drugs: Ramucirumab, Atezolizumab
Study Phase: Phase 2
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Irinotecan
Study Phase: Phase 1/Phase 2
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Enrollment Status: Withdrawn
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

26 Total Publications

Health Insurance Type and Lung Cancer Stage Shift Following Coverage of Screening.
Health Insurance Type and Lung Cancer Stage Shift Following Coverage of Screening.
Journal: Health services research
Published: November 25, 2025
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nancy Bartlett is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Bartlett is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Bone Marrow Aspiration. Dr. Bartlett is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ramaswamy Govindan is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Govindan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Govindan is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Office

4921 Parkview Pl Ste 13C, 
Saint Louis, MO 
 (0.7 miles away)
314-362-3181
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Powell is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Powell is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hernia Surgery, and Vulvectomy. Dr. Powell is currently accepting new patients.

Frequently Asked Questions about Dr. Maria Q. Baggstrom

How do I make an appointment with Dr. Maria Q. Baggstrom?

You can book an appointment with Dr. Maria Q. Baggstrom by calling their office at 314-747-1171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maria Q. Baggstrom a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maria Q. Baggstrom is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maria Q. Baggstrom specialize in?

While Dr. Maria Q. Baggstrom is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Maria Q. Baggstrom participate in research or clinical trials?

Yes. Dr. Maria Q. Baggstrom has published 26 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Maria Q. Baggstrom's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maria Q. Baggstrom accept my insurance?

Dr. Maria Q. Baggstrom accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-747-1171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baggstrom's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile